Key terms
About VNDA
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VNDA news
Apr 17
10:25am ET
Vanda adopts limited duration stockholder rights plan
Apr 17
9:05am ET
Vanda rejects unsolicited acquisition proposal from Future Pak
Apr 17
6:32am ET
Future Pak confirms proposal to acquire Vanda Pharmaceuticals for $7.25-$7.75
Apr 05
10:40am ET
Biotech Alert: Searches spiking for these stocks today
Apr 03
8:17am ET
Vanda (NASDAQ:VNDA) Soars After U.S. FDA Greenlights Fanapt for Bipolar Disorder
Apr 02
6:10pm ET
Vanda Pharmaceuticals’ Fanapt receives FDA approval
Mar 06
7:05am ET
Vanda Pharmaceuticals receives CRL from FDA regarding sNDA for HETLIOZ
Feb 21
4:44pm ET
Vanda Pharmaceuticals Sets New Executive Compensation Packages
Feb 06
4:50am ET
Vanda Pharmaceuticals Shares HETLIOZ® FDA Review Progress
Feb 05
8:04am ET
Vanda Pharmaceuticals announces FDA update for supplemental NDA for Hetlioz
Jan 31
9:04am ET
Vanda Pharmaceuticals: FDA approves IND application to evaluate VTR-297
Jan 30
12:38pm ET
Court orders FDA to resolve Vanda’s jet lag hearing request by March 4
Jan 29
7:03pm ET
Court orders FDA to resolve Vanda Pharmaceuticals’ hearing request on HETLIOZ
Jan 26
5:35am ET
Vanda Pharmaceuticals announces U.S. patent allowance for Ponvory
Jan 25
1:09pm ET
Vanda announces publication of journal article on Tradipitant study
Jan 23
9:18am ET
Vanda Pharmaceuticals’ IND application for VCA-894A granted FDA approval
Jan 19
3:58pm ET
Vanda Pharmaceuticals says court denied in part U.S. motion to dismiss
Mar 29
11:24am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
Mar 21
1:37pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
Mar 13
9:47am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
VNDA Financials
Key terms
Ad Feedback
VNDA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VNDA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
